REGiMMUNE Corporation is a private biopharmaceutical company developing innovative solutions for treating immune disorders caused by nonspecific and/or excessive immune reactions. REGiMMUNE uses its proprietary technology platform, reVax (reverse vaccination), to target immune tolerance against specific disease-causing antigens through induction of regulatory T cells (Treg). This technology has potential applications in a number of immune system disorders and diseases including Graft versus Host Disease (GvHD), type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), multiple sclerosis (MS) and systemic lupus erythematosus (SLE).
Currently, the company has one clinical-stage compound in a Phase I/II trial in the United States (RGI-2001) as a treatment for GvHD associated with hematopoietic stem cell transplantation and has a second product in preclinical development (RGI-3001) as a new treatment for T1DM. In addition, it has a number of well-differentiated compounds in its research-stage pipeline.
In healthy individuals, the normal immune system works to protect humans from disease-causing viruses, bacterium, and cancers; or foreign antigens such as peanuts, wheat and tree pollens. Conventional immunosuppressants have several significant side effects associated with long-term administration including risk of infection, toxicity and relapse. Products developed with ReVax technology are expected to reduce or eliminate such side effects as well as reduce long-term treatment.